Background
Methods
Study population
Statistical analysis
Results
All Epitheilal or Unknown Cases (N = 1170) | Cases With Pre-Diagnosis Platelets Measured (N = 304) | |||
---|---|---|---|---|
Characteristic | N or mean | % or std deva | N or mean | % or std deva |
Age at Diagnosis, years | 58.5 | 13.7 | 60.2 | 14.5 |
Date of Diagnosis, calendar year | ||||
1980–1984 | 117 | 10.0 | ||
1985–1989 | 143 | 12.2 | ||
1990–1994 | 183 | 15.6 | ||
1995–1999 | 202 | 17.3 | 62 | 20.4 |
2000–2004 | 199 | 17.0 | 83 | 27.3 |
2005–2009 | 208 | 17.8 | 100 | 32.9 |
2010–2013 | 118 | 10.1 | 59 | 19.4 |
Race | ||||
White | 1036 | 88.6 | 266 | 87.5 |
Black | 68 | 5.8 | 25 | 8.2 |
Asian | 11 | 0.9 | 2 | 0.7 |
Native | 2 | 0.2 | 0 | 0.0 |
Other/Unknown | 53 | 4.5 | 11 | 3.6 |
Primary Site | ||||
Ovary (C569) | 1129 | 96.5 | 294 | 96.7 |
Fallopian Tube (C570) | 41 | 3.5 | 10 | 3.3 |
Histologic Subtype | ||||
Serous | 666 | 56.9 | 147 | 48.4 |
Endometrioid | 105 | 9.0 | 33 | 10.9 |
Mucinous | 75 | 6.4 | 24 | 7.9 |
Clear Cell | 45 | 3.9 | 15 | 4.9 |
Other | 47 | 4.0 | 18 | 5.9 |
Unknown | 232 | 19.8 | 67 | 22.0 |
Stage of Disease | ||||
I | 172 | 14.7 | 69 | 22.7 |
II | 52 | 4.4 | 19 | 6.3 |
III | 360 | 30.8 | 124 | 40.8 |
IV | 261 | 22.3 | 67 | 22.0 |
Unknown/Unstaged | 325 | 27.8 | 25 | 8.2 |
Disease Grade | ||||
1, Well differentiated | 58 | 5.0 | 21 | 6.9 |
2, Moderately differentiated | 161 | 13.8 | 44 | 14.5 |
3, Poorly differentiated | 412 | 35.2 | 120 | 39.5 |
4, Undifferentiated | 83 | 7.1 | 35 | 11.5 |
Unknown | 456 | 39.0 | 84 | 27.6 |
Overall Survival, years | 4.1 | 3.4 | 3.4 | 3.1 |
Thrombocytosis (>350 × 109/L) | Thrombocytosis (>400 × 109/L) | Thrombocytosis (>450 × 109/L) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No (N = 145) | Yes (N = 159) | No (N = 190) | Yes (N = 114) | No (N = 228) | Yes (N = 76) | ||||||||||
Characteristic | N or mean | (% or std dev)a | P-value** | N or mean | (% or std dev)a | P-value** | N or mean | (% or std dev)a | P-value** | ||||||
Age at Diagnosis, years | 60.7 | (14.1) | 59.9 | (14.8) | 0.631 | 60.9 | (14.3) | 59.1 | (14.8) | 0.275 | 60.4 | (14.4) | 59.8 | (14.8) | 0.746 |
Race | |||||||||||||||
White | 128 | (88.3) | 138 | (86.8) | 0.696 | 169 | (89.0) | 97 | (85.1) | 0.325 | 202 | (88.6) | 64 | (84.2) | 0.317 |
Other/Unknown | 17 | (11.7) | 21 | (13.2) | 21 | (11.1) | 17 | (14.9) | 26 | (11.4) | 12 | (15.8) | |||
Primary Site | |||||||||||||||
Ovary (C569) | 137 | (94.5) | 157 | (98.7) | 0.052 † | 114 | (100.0) | 114 | (100.0) |
0.015 †
| 218 | (95.6) | 76 | (100.0) | 0.072 † |
Fallopian Tube (C570) | 17 | (5.5) | 2 | (1.3) | 0 | (0.0) | 0 | (0.0) | 10 | (4.4) | 0 | (0.0) | |||
Histologic Subtype | |||||||||||||||
Serous | 68 | (46.9) | 79 | (49.7) | 0.691 | 88 | (46.3) | 59 | (51.8) | 0.629 | 111 | (48.7) | 36 | (47.4) | 0.414 |
Endometrioid | 14 | (9.7) | 19 | (12.0) | 20 | (10.5) | 13 | (11.4) | 24 | (10.5) | 9 | (11.8) | |||
Mucinous | 15 | (10.3) | 9 | (5.7) | 19 | (10.0) | 5 | (4.4) | 22 | (9.7) | 2 | (2.6) | |||
Clear Cell | 6 | (4.1) | 9 | (5.7) | 9 | (4.7) | 6 | (5.3) | 10 | (4.4) | 5 | (6.6) | |||
Other | 9 | (6.2) | 9 | (5.7) | 11 | (5.8) | 7 | (6.1) | 12 | (5.3) | 6 | (7.9) | |||
Unknown | 33 | (22.8) | 34 | (21.4) | 43 | (22.6) | 24 | (21.1) | 49 | (21.5) | 18 | (23.7) | |||
Serous | 68 | (46.9) | 79 | (49.7) | 0.888 | 88 | (46.3) | 59 | (51.8) | 0.646 | 111 | (48.7) | 36 | (47.4) | 0.923 |
Non-Serous | 44 | (30.3) | 46 | (28.9) | 59 | (31.1) | 31 | (27.2) | 68 | (29.8) | 22 | (29.0) | |||
Unknown | 33 | (22.8) | 34 | (21.4) | 43 | (22.6) | 24 | (21.1) | 49 | (21.5) | 18 | (23.7) | |||
Stage of Disease | |||||||||||||||
I | 43 | (29.7) | 26 | (16.4) | 0.051 | 52 | (27.4) | 17 | (14.9) |
0.038
| 59 | (25.9) | 10 | (13.2) |
0.009
|
II | 10 | (6.9) | 9 | (5.7) | 14 | (7.4) | 5 | (4.4) | 17 | (7.5) | 2 | (2.6) | |||
III | 56 | (38.6) | 68 | (42.8) | 76 | (40.0) | 48 | (42.1) | 94 | (41.2) | 30 | (39.5) | |||
IV | 25 | (17.2) | 42 | (26.4) | 35 | (18.4) | 32 | (28.1) | 43 | (18.9) | 24 | (31.6) | |||
Unknown/Unstaged | 11 | (7.6) | 14 | (8.8) | 13 | (6.8) | 12 | (10.5) | 15 | (6.6) | 10 | (13.2) | |||
Disease Grade | |||||||||||||||
1, Well differentiated | 10 | (6.9) | 11 | (6.9) | 0.115 | 15 | (7.9) | 6 | (5.3) |
0.008
| 18 | (7.9) | 3 | (4.0) |
0.010
|
2, Moderately differentiated | 21 | (14.5) | 23 | (14.5) | 29 | (15.3) | 15 | (13.2) | 36 | (15.8) | 8 | (10.5) | |||
3, Poorly differentiated | 57 | (39.3) | 63 | (39.6) | 78 | (41.1) | 42 | (36.8) | 90 | (39.5) | 30 | (39.5) | |||
4, Undifferentiated | 10 | (6.9) | 25 | (15.7) | 12 | (6.3) | 23 | (20.2) | 18 | (7.9) | 17 | (22.4) | |||
Unknown | 47 | (32.4) | 37 | (23.3) | 56 | (29.5) | 28 | (24.6) | 66 | (29.0) | 18 | (23.7) |
Thrombocytosis | No Thrombocytosis (Reference) | Unadjusted Association | Multivariable Associationa | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Thrombocytosis | % | N Cases | N Events | N Cases | N Events | HR | 95 % CI | P-value* | HR | 95 % CI | P-value* |
Defined by ≥350 × 109/L | |||||||||||
Date of diagnosis | 44.8 | 61 | 42 | 75 | 46 | 1.45 | 0.94–2.23 | 0.093 | 1.55 | 0.97–2.47 | 0.070 |
1 week prior to date of diagnosis | 53.1 | 128 | 96 | 113 | 63 |
2.09
|
1.51–2.89
|
<0.001
|
1.83
|
1.30–2.58
|
0.001
|
2 week prior to date of diagnosis | 52.5 | 147 | 106 | 133 | 72 |
1.96
|
1.47–2.66
|
<0.001
|
1.79
|
1.31–2.44
|
<0.001
|
4 week prior to date of diagnosis | 53.2 | 158 | 110 | 139 | 73 |
1.94
|
1.44–2.62
|
<0.001
|
1.80
|
1.33–2.45
|
<0.001
|
8 week prior to date of diagnosis | 52.3 | 159 | 111 | 145 | 77 |
1.92
|
1.43–2.58
|
<0.001
|
1.80
|
1.33–2.43
|
<0.001
|
Defined by ≥400 × 109/L | |||||||||||
Date of diagnosis | 31.6 | 43 | 33 | 93 | 60 |
1.98
|
1.27–3.09
|
0.003
|
2.01
|
1.25–3.23
|
0.004
|
1 week prior to date of diagnosis | 39.4 | 95 | 73 | 146 | 94 |
1.92
|
1.39–2.64
|
<0.001
|
1.62
|
1.16–2.26
|
0.005
|
2 week prior to date of diagnosis | 38.2 | 107 | 79 | 173 | 108 |
1.87
|
1.39–2.53
|
<0.001
|
1.60
|
1.17–2.18
|
0.003
|
4 week prior to date of diagnosis | 38.1 | 113 | 80 | 184 | 112 |
1.78
|
1.32–2.40
|
<0.001
|
1.54
|
1.14–2.09
|
0.006
|
8 week prior to date of diagnosis | 37.5 | 114 | 81 | 190 | 116 |
1.78
|
1.33–2.40
|
<0.001
|
1.55
|
1.14–2.10
|
0.005
|
Defined by ≥450 × 109/L | |||||||||||
Date of diagnosis | 19.9 | 27 | 22 | 109 | 71 |
1.98
|
1.21–3.27
|
0.007
|
2.00
|
1.16–3.46
|
0.013
|
1 week prior to date of diagnosis | 26.1 | 63 | 51 | 178 | 116 |
2.01
|
1.43–2.82
|
<0.001
|
1.71
|
1.20–2.45
|
0.003
|
2 week prior to date of diagnosis | 25.7 | 72 | 55 | 208 | 132 |
1.91
|
1.38–2.65
|
<0.001
|
1.62
|
1.16–2.27
|
0.005
|
4 week prior to date of diagnosis | 24.9 | 74 | 56 | 223 | 136 |
1.88
|
1.37–2.59
|
<0.001
|
1.56
|
1.12–2.17
|
0.008
|
8 week prior to date of diagnosis | 25.0 | 76 | 57 | 228 | 140 |
1.79
|
1.30–2.45
|
<0.001
|
1.55
|
1.12–2.15
|
0.009
|
Thrombocytosis | No Thrombocytosis | Unadjusted Association | Multivariable Associationa | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Thrombocytosis | N Cases | N Events | N Cases | N Events | HR | 95 % CI | P-value* | HR | 95 % CI | P-value* |
Defined by ≥350 × 109/L | ||||||||||
2 weeks to date of diagnosis | 147 | 106 | 133 | 72 |
1.96
|
1.45–2.66
|
<0.001
|
1.78
|
1.31–2.44
|
<0.001
|
Excluding low malignant potential tumors | 147 | 106 | 121 | 71 |
1.71
|
1.26–2.32
|
<0.001
|
1.67
|
1.22–2.28
|
0.001
|
Excluding synchronous cancers | 134 | 101 | 124 | 71 |
1.94
|
1.42–2.64
|
<0.001
|
1.72
|
1.26–2.36
|
<0.001
|
Excluding non–Whites | 128 | 91 | 114 | 61 |
1.92
|
1.38–2.68
|
<0.001
|
1.88
|
1.34–2.62
|
<0.001
|
Excluding unknown stage of disease | 134 | 95 | 124 | 67 |
1.89
|
1.37–2.60
|
<0.001
|
1.66
|
1.20–2.30
|
0.002
|
Excluding unknown histologic subtypes | 115 | 79 | 104 | 52 |
1.81
|
1.27–2.58
|
0.001
|
1.48
|
1.03–2.13
|
0.034
|
Excluding all of the above cases | 84 | 60 | 68 | 40 | 1.47 | 0.98–2.20 | 0.063 | 1.47 | 0.98–2.21 | 0.065 |
Defined by ≥400 × 109/L | ||||||||||
2 weeks to date of diagnosis | 107 | 78 | 173 | 100 |
1.87
|
1.39–2.53
|
<0.001
|
1.60
|
1.17–2.18
|
0.003
|
Excluding low malignant potential tumors | 107 | 78 | 161 | 99 |
1.67
|
1.23–2.26
|
<0.001
|
1.50
|
1.10–2.06
|
0.010
|
Excluding synchronous cancers | 96 | 74 | 162 | 98 |
1.94
|
1.42–2.64
|
<0.001
|
1.61
|
1.17–2.20
|
0.003
|
Excluding non–Whites | 91 | 64 | 151 | 88 |
1.75
|
1.26–2.43
|
<0.001
|
1.58
|
1.13–2.21
|
0.008
|
Excluding unknown stage of disease | 96 | 69 | 162 | 93 |
1.84
|
1.34–2.52
|
<0.001
|
1.49
|
1.08–2.07
|
0.016
|
Excluding unknown histologic subtypes | 84 | 59 | 135 | 72 |
1.81
|
1.28–2.57
|
<0.001
| 1.37 | 0.95–1.97 | 0.089 |
Excluding all of the above cases | 59 | 44 | 93 | 56 |
1.69
|
1.13–2.53
|
0.011
| 1.46 | 0.97–2.20 | 0.072 |
Defined by ≥450 × 109/L | ||||||||||
2 weeks to date of diagnosis | 72 | 55 | 208 | 123 |
1.91
|
1.38–2.65
|
<0.001
|
1.62
|
1.16–2.27
|
0.005
|
Excluding low malignant potential tumors | 72 | 55 | 196 | 122 |
1.73
|
1.25–2.39
|
<0.001
|
1.53
|
1.09–2.14
|
0.014
|
Excluding synchronous cancers | 64 | 51 | 194 | 121 |
1.92
|
1.38–2.68
|
<0.001
|
1.66
|
1.17–2.34
|
0.004
|
Excluding non–Whites | 60 | 44 | 182 | 108 |
1.82
|
1.27–2.61
|
0.001
|
1.65
|
1.14–2.40
|
0.008
|
Excluding unknown stage of disease | 63 | 47 | 195 | 115 |
1.88
|
1.33–2.65
|
<0.001
|
1.51
|
1.05–2.15
|
0.024
|
Excluding unknown histologic subtypes | 54 | 41 | 165 | 90 |
1.81
|
1.24–2.63
|
0.002
| 1.31 | 0.88–1.94 | 0.186 |
Excluding all of the above cases | 37 | 29 | 115 | 71 |
1.73
|
1.11–2.70
|
0.016
| 1.49 | 0.93–2.37 | 0.096 |